1 active not recruiting, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Diffuse Large B-cell-lymphoma: new trials by email Literature Review of Diffuse Large B-cell-lymphoma trials Research Report on Diffuse Large B-cell-lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma C402-CD19-CAR - Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Recruiting | Shanghai Exuma Biotechnology Ltd. | 18 | 2025-03-25 | 2026-09-11 |
| Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Venetoclax, Rituximab, Ifosfamide - Diffuse Large B-cell-lymphoma | Phase 1 / Phase 2 | Active not recruiting | Molly Gallogly | 65 | 2017-06-26 | 2022-11-16 |
Dendritic Cell Sarcoma, Interdigitating (2) · Lymphoma, B-Cell (1) · Pyloric Stenosis, Hypertrophic (1)
Hemic and Lymphatic Diseases (2) · Histiocytic Disorders, Malignant (2) · Histiocytosis (2) · Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Digestive System Diseases (1) · Gastric Outlet Obstruction (1) · Gastrointestinal Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Pyloric Stenosis (1)
Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Rituximab (1) · venetoclax (1)
Molly Gallogly (1) · Shanghai Exuma Biotechnology Ltd. (1)
China (1) · United States (1)
Liang Huang, MD (1) · Molly Gallogly, MD PhD (1)